198 related articles for article (PubMed ID: 26426603)
21. The wizards of odds: cost-effectiveness, Barrett's screening, and surveillance guidelines.
Perdue DG; Murray J; Wang KK
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):865-7. PubMed ID: 15476149
[No Abstract] [Full Text] [Related]
22. Should we screen patients for Barrett's esophagus? No: the case against screening.
Knox MA
Am Fam Physician; 2011 May; 83(10):1148, 1150. PubMed ID: 21568247
[No Abstract] [Full Text] [Related]
23. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus.
Gupta N; Gaddam S; Wani SB; Bansal A; Rastogi A; Sharma P
Gastrointest Endosc; 2012 Sep; 76(3):531-8. PubMed ID: 22732877
[TBL] [Abstract][Full Text] [Related]
24. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus.
Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A
Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675
[TBL] [Abstract][Full Text] [Related]
25. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance.
Rana PS; Johnston DA
Dis Esophagus; 2000; 13(1):28-31. PubMed ID: 11005328
[TBL] [Abstract][Full Text] [Related]
26. Screening and surveillance of Barrett's esophagus.
Regula J
Dig Dis; 2009; 27(1):54-7. PubMed ID: 19439961
[TBL] [Abstract][Full Text] [Related]
27. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients.
Peters JH; Clark GW; Ireland AP; Chandrasoma P; Smyrk TC; DeMeester TR
J Thorac Cardiovasc Surg; 1994 Nov; 108(5):813-21; discussion 821-2. PubMed ID: 7967662
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
Hur C; Nishioka NS; Gazelle GS
J Natl Cancer Inst; 2004 Feb; 96(4):316-25. PubMed ID: 14970280
[TBL] [Abstract][Full Text] [Related]
29. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
Heberle CR; Omidvari AH; Ali A; Kroep S; Kong CY; Inadomi JM; Rubenstein JH; Tramontano AC; Dowling EC; Hazelton WD; Luebeck EG; Lansdorp-Vogelaar I; Hur C
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1397-1404.e7. PubMed ID: 28238953
[TBL] [Abstract][Full Text] [Related]
30. Barrett's oesophagus: a review of costs of the illness.
Arguedas MR; Eloubeidi MA
Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
[TBL] [Abstract][Full Text] [Related]
31. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
Inadomi JM; Sampliner R; Lagergren J; Lieberman D; Fendrick AM; Vakil N
Ann Intern Med; 2003 Feb; 138(3):176-86. PubMed ID: 12558356
[TBL] [Abstract][Full Text] [Related]
32. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma].
Incarbone R; Bonavina L; Bassi F; Peracchia A
Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454
[TBL] [Abstract][Full Text] [Related]
33. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study.
Verbeek RE; Leenders M; Ten Kate FJ; van Hillegersberg R; Vleggaar FP; van Baal JW; van Oijen MG; Siersema PD
Am J Gastroenterol; 2014 Aug; 109(8):1215-22. PubMed ID: 24980881
[TBL] [Abstract][Full Text] [Related]
34. BarrettNET-a prospective registry for risk estimation of patients with Barrett's esophagus to progress to adenocarcinoma.
Wiethaler M; Slotta-Huspenina J; Brandtner A; Horstmann J; Wein F; Baumeister T; Radani N; Gerland S; Anand A; Lange S; Schmidt M; Janssen KP; Conrad A; Johannes W; Strauch K; Quante AS; Linkohr B; Kuhn KA; Blaser R; Lehmann A; Kohlmayer F; Weichert W; Schmid RM; Becker KF; Quante M
Dis Esophagus; 2019 Aug; 32(8):. PubMed ID: 31329831
[TBL] [Abstract][Full Text] [Related]
35. Innovations in Screening Tools for Barrett's Esophagus and Esophageal Adenocarcinoma.
Bell MG; Iyer PG
Curr Gastroenterol Rep; 2021 Oct; 23(12):22. PubMed ID: 34654955
[TBL] [Abstract][Full Text] [Related]
36. Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile?
Otaki F; Iyer PG
Dig Dis Sci; 2018 Aug; 63(8):2081-2093. PubMed ID: 29713986
[TBL] [Abstract][Full Text] [Related]
37. Esophageal Adenocarcinoma: Screening, Surveillance, and Management.
Mansour NM; Groth SS; Anandasabapathy S
Annu Rev Med; 2017 Jan; 68():213-227. PubMed ID: 27618753
[TBL] [Abstract][Full Text] [Related]
38. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
Provenzale D; Schmitt C; Wong JB
Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
[TBL] [Abstract][Full Text] [Related]
39. Surveillance of patients with long-segment Barrett's esophagus: A multicenter prospective cohort study in Japan.
Matsuhashi N; Sakai E; Ohata K; Ishimura N; Fujisaki J; Shimizu T; Iijima K; Koike T; Endo T; Kikuchi T; Inayoshi T; Amano Y; Furuta T; Haruma K; Kinoshita Y
J Gastroenterol Hepatol; 2017 Feb; 32(2):409-414. PubMed ID: 27416773
[TBL] [Abstract][Full Text] [Related]
40. Screening and surveillance of Barrett's esophagus.
Michalak J; Bansal A; Sharma P
Curr Gastroenterol Rep; 2009 Jun; 11(3):195-201. PubMed ID: 19463219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
